| Literature DB >> 17497001 |
D Shanker1, A K Rai, Y P Singh, H Rehwani, V Khushalani, R S Gupta.
Abstract
Benzothiazoline HNC(6)H(4)SC(C6H5)CH:C(OH)COOCH(3) 1 prepared by the condensation reaction of aroyl pyruvate and 2-aminothiophenol has been treated with Ph(3)Sb(OPr(i))(2) to yield Ph(3)Sb[SC(6)H(4)NC(C6H5)CH:COCOOCH(3)] 2. These compounds have been characterized by elemental analyses and molecular weight determinations. The probable structures of the ligand as well as antimony complex have been tentatively proposed on the basis of IR and NMR ((1)H and (13)C) spectral evidences. Both compounds have been tested for their antifertility activity in male albino rats. The oral administration of compounds 1 and 2 at the dose level of 10 mg/rat/day significantly reduced the weights of testes, epididymides, ventral prostate, and seminal vesicles. The production of preleptotene spermatocytes was decreased by 36.57%; 57.23%, pachytene spermatocytes by 40.06%; 62.01%, and secondary spermatocytes by 52.45%; 63.22%, following the treatment of compounds 1 and 2, respectively. The marked reduction in sperm motility and density resulted in infertility by 100%. Significant (P < .01) alterations were found in biochemical parameters of reproductive organs in treated animals as compared to control group. It is concluded that all these effects may finally impair the fertility of male rats.Entities:
Year: 2006 PMID: 17497001 PMCID: PMC1686296 DOI: 10.1155/BCA/2006/20979
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Effects of compounds 1 and 2 on the body and organ weights (Gr I: rat receiving vehicle (olive oil 0.5 ml/day) gavage orally for 60 days; Gr II: rat treated with compound 1 (10 mg/rat/day) gavage orally for 60 days; Gr III: rat treated with compound 2 (10 mg/rat/day) gavage orally for 60 days; values are mean ± SEM (n = 6)).
| Treatment | Final body weight (g) | Organ weights (mg/100 g.b.wt) | |||
|
| |||||
|---|---|---|---|---|---|
| Testes | Epididymides | Seminal vesicles | Ventral prostate | ||
|
| |||||
| Gr I | 250 ± 3.4 | 1460 ± 22.0 | 686.45 ± 16.55 | 720.55 ± 19.0 | 490.25 ± 26.0 |
| Gr II | 222.5 ± 11.5 | 1211.81 ± 11.11 | 560.74 ± 20.77 | 704.22 ± 43.41 | 275.36 ± 0.52 |
| Gr III | 187.5 ± 25.56 | 1167.86 ± 10.57 | 470.57 ± 10.57 | 565.27 ± 24.44 | 205.91 ± 14.66 |
Level of significance, *P < .01, **P < .001 compared with Gr I (controls).
Level of significance, a P < .01 compared with Gr II (compound 1 treated group).
Effects of compounds 1 and 2 on blood and serum profile (values are mean ± SEM (n = 6)).
| R.B.C. | W.B.C. (mm3) | Haemo- | Haematocrit | Blood | ||||||
| Treatment | (million/ | globin | value | Sugar | Protein | Cholesterol | Phospholipid | Triglyceride | HDL-Cholesterol | |
| mm3) | (g%) | (%) | (mg/dl) | |||||||
|
| ||||||||||
| Gr I | 5.54 | 8390 | 14.45 | 41.50 | 90.85 | 13555.54 | 106.48 | 118.20 | 105.60 | 40.60 |
| Control | ±0.10 | ±55 | ±0.22 | ±1.05 | ±2.45 | ±222.20 | ±3.30 | ±2.67 | ±5.15 | ±2.8 |
| Gr II | 5.39 | 8350 | 13.85 | 39.00 | 82.81 | 13111.09 | 100.54 | 111.00 | 94.17 | 40.00 |
| DI treated | ±0.10 | ±50 | ±0.49 | ±0.86 | ±4.85 | ±111.10 | ±2.28 | ±3.20 | ±3.60 | ±2.20 |
| Gr III | 5.42 | 8275 | 14.05 | 38.05 | 90.62 | 12666.65 | 93.05 | 106.65 | 92.00 | 38.70 |
| DII treated | ±0.14 | ±52 | ±0.12 | ±1.3 | ±3.13 | ±444.40 | ±2.98 | ±6.85 | ±6.00 | ±2.95 |
Scheme 1Structure of .
Scheme 2Structure of .
Sperm dynamics and fertility after the treatment of compounds 1 and 2 (values are mean ± SEM (n = 6)).
| Treatment | Sperm motility (%) (cauda epididymides) | Sperm density (million/ml) | Implantation sites/ litter delivered | Fertility (%) | ||
|
| ||||||
| Testes | Cauda | Prefertility | Postfertility | |||
| epididymides | test | test | ||||
|
| ||||||
| Gr I | 65.55 ± 1.98 | 4.6 ± 0.35 | 45.15 ± 1.44 | 10 ± 0.81 | 10.66 ± 0.47 | 100 |
| Gr II | 19.75 ± 0.66 | 2.68 ± 0.20 | 10.75 ± 0.90 | 10.66 ± 0.47 | 0 | 0 |
| Gr III | 16.14 ± 1.03 | 1.59 ± 0.28 | 6.65 ± 1.05 | 10.33 ± 0.74 | 0 | 0 |
Level of significance; *P < .01; **P < .001 compared with Gr I (control).
Level of significance; a P < .01 compared with Gr II (compound 1 treated group).
Figure 3Microphotograph of testis of rat treated with compound 2 showing incomplete spermatogenesis. Seminiferous tubular size is reduced. Secondary spermatocyte stage showing degeneration. Lumen is devoid of sperm. X 200 HE.
Figure 2Microphotograph of testis of rat treated with compound 1 showing acute degenerative changes in the histoarchitecture of testis and detachment of germinal epithelial layer. Degeneration of primary spermatocyte stage is seen and lumen is filled with cellular debris. X 200 HE.
Testicular cell population dynamics following the treatment of compounds 1 and 2 (values are mean ± SEM (n = 6)).
| Treatment | Testicular cell counts (number/10 cross-section) | Seminiferous tubular diameter ( | ||||
|
| ||||||
| Sertoli cell | Spermatogonia | Preleptotene spermatocytes | Pachytene spermatocytes | Secondary spermatocytes | ||
|
| ||||||
| Gr I | 2.82 ± 0.04 | 7.58 ± 1.20 | 20.18 ± 1.85 | 30.20 ± 1.08 | 45.60 ± 3.50 | 276 ± 9.0 |
| Gr II | 1.98 ± 0.05 | 5.72 ± 0.52 | 12.8 ± 1.1 | 18.10 ± 0.90 | 21.68 ± 0.90 | 215.2 ± 2.15 |
| (Percent deviation) | (−29.78%) | (−24.53%) | (−36.57%) | (−40.06%) | (−52.45%) | (−22.02%) |
| Gr III | 1.65 ± 0.10 | 3.80 ± 0.45 | 8.63 ± 0.85 | 11.47 ± 2.2 | 16.77 ± 1.34 | 241.3 ± 2.42 |
| (Percent deviation) | (−41.48%) | (−49.86%) | (−57.23%) | (−62.01%) | (−63.22%) | (−12.57%) |
Level of significance; *P < .01; **P < .001 compared with Gr I (controls).
Level of significance; a P < .01 compared with Gr II (compound 1 treated group).
cValues in parentheses are percentage reduction in particular cell type.
Effects on certain biochemical parameters following the treatment of compounds 1 and 2 (values are mean ± SEM (n = 6)).
| Treatment | ||||
| Gr I | Gr II | Gr III | ||
|
| ||||
| Protein (mg/g) | Testes | 210.50 ± 4.15 | 161.5 ± 2.25 | 147.6 ± 3.88 |
| Cauda epididymides | 218.00 ± 3.64 | 180.2 ± 3.32 | 161.5 ± 4.40 | |
| Seminal vesicles | 228.65 ± 2.90 | 177.75 ± 3.15 | 183.05 ± 3.22 | |
| Ventral prostate | 198.05 ± 2.88 | 164.70 ± 2.9 | 157.0 ± 3.10 | |
|
| ||||
| Sialic acid (mg/g) | Testes | 4.80 ± 0.90 | 4.30 ± 0.03 | 3.92 ± 0.09 |
| Cauda epididymides | 5.25 ± 0.11 | 4.32 ± 0.10 | 4.02 ± 0.12 | |
| Seminal vesicles | 4.80 ± 0.13 | 4.12 ± 0.07 | 3.69 ± 0.03 | |
| Ventral prostate | 5.70 ± 0.10 | 4.14 ± 0.06 | 3.99 ± 0.09 | |
|
| ||||
| Glycogen (mg/g) | Testes | 3.98 ± 0.11 | 3.20 ± 0.14 | 2.48 ± 0.18 |
|
| ||||
| Fructose (mg/g) | Testes | 4.65 ± 0.10 | 3.20 ± 0.05 | 2.80 ± 0.12 |
|
| ||||
| Cholesterol (mg/g) | Testes | 6.78 ± 0.16 | 9.18 ± 0.11 | 9.56 ± 0.28 |
Level of significance; *P < .01; **P < .001 compared with Gr I (controls).
Level of significance; a P < .01 b P < .001 compared with Gr II (compound 1 treated group).